hVIVO PLC Notice of Results (7237W)

TIDMHVO

RNS Number : 7237W

hVIVO PLC

19 April 2023

19 April 2023

hVIVO plc

("hVIVO" or the "Company")

Notice of results

hVIVO plc (AIM & Euronext: HVO) , (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it will release its audited final results for the twelve months ended 31 December 2022 on Tuesday 25 April 2023.

Investor presentation

Yamin 'Mo' Khan, Chief Executive Officer, and Stephen Pinkerton, Chief Financial Officer, will provide a live presentation relating to the final results via the Investor Meet Company platform on Tuesday 25 April 2023 at 17:00 BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet hVIVO here . Investors who already follow hVIVO on the Investor Meet Company platform will automatically be invited.

For further information please contact:

 
 hVIVO plc                                                           [phone] 
 Yamin 'Mo' Khan, Chief Executive 
  Officer 
  Stephen Pinkerton, Chief Financial 
  Officer 
 
 Liberum Capital (Nominated Adviser and 
  Joint Broker)                                                      [phone] 
 Ben Cryer, Edward Mansfield, Phil Walker, 
  Will King 
 
 finnCap plc (Joint Broker)                                          [phone] 
 Geoff Nash, Charlie Beeson, Nigel Birks, 
  Harriet Ward (ECM) 
 
 Davy (Euronext Growth Adviser and Joint 
  Broker)                                                             [phone] 
 Anthony Farrell, Niall Gilchrist 
 
 Walbrook PR (Financial PR & IR)             [phone] or [e-mail] 
  Stephanie Cuthbert / Phillip                    [phone] / [phone] 
  Marriage /                                                                        082 / 
  Louis Ashe-Jepson                                                  [phone] 
 
 

Notes to Editors

About hVIVO

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Company has world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORGLGDSIGBDGXC

(END) Dow Jones Newswires

April 19, 2023 02:10 ET (06:10 GMT)